Status
Conditions
About
Many studies have focused on patients treated with allogeneic peripheral stem cell transplantation; few studies have until now been carried out to describe the characteristics and results of autografted patients and to attempt to determine possible prognostic factors. However, it is estimated that nearly 5% of autograft patients require MIR care. The investigators therefore wish to conduct a retrospective study including patients treated by therapeutic intensification followed by autograft of hematopoietic stem cells and admitted to the MIR department of the Hautepierre hospital of the University Hospitals of Strasbourg (HUS) within thirty days following initiation of chemotherapy.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Loading...
Central trial contact
Vincent CASTELAIN, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal